Treatment News : Pooled Trial Results Suggest Capsaicin Patch Relieves Neuropathy Pain

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 28, 2011

Pooled Trial Results Suggest Capsaicin Patch Relieves Neuropathy Pain

The pooled results of two clinical trials suggest that a skin patch with the chili pepper–derived chemical capsaicin could relieve HIV-related neuropathy pain by about 30 percent. These trial results, presented at the annual meeting of the American Academy of Pain Medicine (AAPM), were reported by the website Medpage Today.

Chili peppers and mustards have been used for centuries in topical balms to treat chronic pain. Only during the past few decades, however, have scientists figured out how capsaicin—the chemical that gives chilies their pungency—works as an analgesic: It depletes a neurochemical called substance P responsible for transmitting pain.

NeurogesX, based in San Mateo, California, has spent several years testing capsaicin in skin patches to treat a variety of chronic pain conditions. The company now has a skin patch made up of a gel containing 8 percent capsaicin, called Qutenza, which is approved by the U.S. Food and Drug Administration (FDA) to treat pain from shingles and from diabetic neuropathy. Qutenza is applied for one hour in a single application, and the pain-relief lasts for about three months.

NeurogesX has also conducted trials of Qutenza to treat HIV-related distal sensory polyneuropathy (neuropathy), a condition marked by nerve damage, which can cause pain, tingling and numbness in the extremities and sometimes lead to permanent disability.

“To date, medications used to treat neuropathic pain have yielded disappointing results in large randomized controlled studies among HIV-associated neuropathy,” Steven Brown, MD, from the AIDS Research Alliance in Los Angeles, told Medpage Today.

Brown, who presented the results of the two trials at the AAPM conference, also noted: “The only substances that have shown any impact on the pain appear to be the [Qutenza] patch, smoked cannabis and recombinant human nerve growth factor, but none of these treatments has yet been approved by the FDA for that use.”

Two clinical trials of Qutenza for HIV-related neuropathy conducted before 2008 had mixed results, with one showing improvements in neuropathy pain and another finding that Qutenza wasn’t significantly better than a gel patch containing a miniscule amount of capsaicin. A 2009 article in Wired magazine detailed how the placebo effect—whereby patients’ symptoms can significantly improve just by thinking they are getting a real medicine, even if they receive only a sugar pill—is particularly strong in trials of pain medication. This means that a medicine often has to be quite potent to show a statistical difference.

At the recent AAPM conference, Brown presented data on an analysis that pooled the results of two newer studies. The studies compared 239 people who received a single application of Qutenza (8 percent capsaicin) with 99 people who received a single application of a control patch containing only 0.04 percent capsaicin.

Brown and his colleagues found that those receiving Qutenza had a 27 percent decrease in their neuropathy pain compared with a 15.7 percent decrease in those who received the control patch. The improvement was highly statistically significant, meaning that the difference between Qutenza and the control was too large to have occurred by chance.

What’s more, when Brown’s team looked at those who received a higher degree of pain relief—a 30 percent or more reduction in pain scores—36 percent of those on Qutenza saw this higher level of relief compared with 22 percent on the active control.

The three-month improvement in neuropathy pain doesn’t come without side effects, however. David Walk, MD, of the University of Minnesota in Minneapolis, who has used Qutenza for non-HIV pain care, told Medpage Today, “This treatment can be painful. Even with the lidocaine that is delivered before the patch is applied, patients report some pain associated with the patch for as long as a week afterward, so we usually send them home with analgesia to cover that period.”

NeurogesX reports on its web site that it is still working to seek FDA approval for Qutenza for HIV-related neuropathy.

Search: Chili pepper, capsaicin, Qutenza, NeurogesX, neuropathy, distal sensory polyneuropathy, Steven Brown, David Walk, skin patch


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (2 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.